Stephens Consulting’s NovoCure NVCR Stock Holding History

Stephens Consulting’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-40	Closed	-$713	–	1719
2025 Q1	$713	Buy	+40	New	+$908	﹤0.01%	811

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Stephens Consulting's NVCR Position: Q2 2025 in Review

Stephens Consulting sold out of NovoCure (NVCR) in Q2 2025, closing a stake of 40 shares — an estimated $713 sold.

Stephens Consulting first reported a position in NVCR in Q1 2025 and held it in 1 quarter. The position peaked at $713 in Q1 2025. 242 funds tracked by Wall St. Rank hold NVCR as of Q2 2025.

Stephens Consulting reported no remaining NovoCure position as of Q2 2025 after selling out during the quarter.
Stephens Consulting sold 40 NovoCure shares in Q2 2025, an estimated $713.
Stephens Consulting first reported a position in NovoCure in Q1 2025 and held it in 1 quarter.
Stephens Consulting's NovoCure position peaked at $713 in Q1 2025.
242 funds tracked by Wall St. Rank held NovoCure as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.